A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

Inclusion Criteria:

* Patients must have clinically documented primary brain tumor for which resection is clinically indicated. The anticipated histology at resection should include: Anaplastic astrocytoma, Astrocytoma, Brain stem glioma, Ependymoma, Glioblastoma, Glioblastoma multiforme, Gliosarcoma, oligodendroglioma, Medulloblastoma, Mixed astrocytoma-ependymoma
* Patients may have prior therapy
* 18 years of age
* Male or Female
* Life expectancy is not a consideration for protocol entry
* Patients must have normal organ and marrow function as defined below: Leukocytes \>3,000/mL, Absolute neutrophil count \>1,500/mL, Platelets \>100,000/mL, Total bilirubin within normal institutional limits AST (SGOT)/ALT (SGPT)\<2.5 X institutional upper limit of normal, Creatinine within normal institutional limits or Creatinine clearance \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
* Confirmation of Glial Tumor
* Gross total resection is the aim of surgery
* Ability to understand and the willingness to sign a written informed consent document or have a parent or guardian with the ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Non-Glial tumor i.e. tumor abscess, metastasis, lymphoma, vasculitis
* Tumor with perforating vessels
* Tumor involves critical fiber tracks
* Use of the microsurgical tool monopolar loop
* Subject has preexisting severe deficits concerning language or motor function not resolved with steroids
* Performance Status of less than 60
* Prior therapy is not an exclusion criterion
* Patients may not be receiving any other investigational agents
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic acid (ALA)
* Personal or family history of porphorias
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements